ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
62 825,08
-0,10%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Telesis Bio Inc (TBIO)

  7. Telesis Bio Inc (TBIO) Actualités

TBIO Telesis Bio Inc

0,3135
-0,0407 (-11,49%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Telesis Bio Inc TBIO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0407 -11,49% 0,3135 22:52:22
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,3396 0,3162 0,3591 0,33 0,3542
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202415:00GLOBETelesis Bio Inc. announces strategic focus on game-changing..
28/3/202421:05GLOBETelesis Bio Reports Fourth Quarter and Full Year 2023..
06/3/202400:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202400:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202402:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202423:00EDGAR2Form 8-K - Current report
26/2/202415:15GLOBETelesis Bio Announces Select Preliminary Fourth Quarter..
30/11/202323:00EDGAR2Form 8-K - Current report
13/11/202322:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:32EDGAR2Form 8-K - Current report
13/11/202322:22GLOBETelesis Bio Reports Third Quarter 2023 Financial Results
09/11/202323:00EDGAR2Form 8-K - Current report
07/11/202315:00GLOBETelesis Bio to Report Third Quarter Financial Results on..
03/11/202317:00GLOBETelesis Bio Announces Commercial Release of Cell-free..
24/10/202322:30EDGAR2Form 8-K - Current report
28/9/202321:48GLOBETelesis Bio Announces Commercial Release of BioXp® NGS..
22/9/202323:00EDGAR2Form 8-K - Current report
29/8/202322:05GLOBETelesis Bio Appoints William J. Kullback Chief Financial..
29/8/202322:02EDGAR2Form 8-K - Current report
11/8/202312:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:17EDGAR2Form 8-K - Current report
10/8/202322:05GLOBETelesis Bio Reports Second Quarter 2023 Financial Results
04/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
03/8/202323:00GLOBETelesis Bio to Report Second Quarter Financial Results on..
27/7/202323:28EDGAR2Form S-3 - Registration statement under Securities Act of..
07/7/202322:01EDGAR2Form 8-K - Current report
08/6/202315:05GLOBETelesis Bio to Present at Jefferies Healthcare Conference..
06/6/202309:00GLOBETelesis Bio to Present at Antibody Engineering and..
05/6/202323:30GLOBETelesis Bio Announces Closing of $28.0 Million Private..
31/5/202323:29GLOBETelesis Bio Secures Financing of $28.0 Million
23/5/202315:00GLOBETelesis Bio to Present at SynBioBeta 2023
22/5/202318:00GLOBETelesis Bio Announces First Commercial Shipment of BioXp®..
18/5/202316:00GLOBETelesis Bio Announces First Commercial Shipment of BioXp®..
15/5/202315:00GLOBETelesis Bio to Present at Protein Engineering Summit (PEGS..
11/5/202322:05GLOBETelesis Bio Reports First Quarter 2023 Financial Results

Dernières Valeurs Consultées

NASDAQ
TBIO
Telesis Bio
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés